Pharmaceutical

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.

Jan 9, 2024 - 18:00
AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval
AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.
Read the original article

Tags:

Previous Article

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood o...

Next Article

Successful Phase 3 Trials Propel Innovent’s Mazdutide into China’s Obesity Market

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage lays off 55% of R&D workforce and refocuses pipeline

Oct 18, 2024

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

STAT+: FDA is blasted by advocates for pursuing a deal ...

Jan 4, 2024

BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using avpal variant

BioMarin Pharmaceutical gets grant for treatment of ado...

Jun 12, 2024